Jenny Worthington

Jenny Worthington

Auto-generated profile, based on publicly available information

Jenny Worthington

Biomedical Science Research Institute, University of Ulster, Coleraine, Londonderry, Northern Ireland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2008 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
Karl ButterworthKarl Butterworth
Karl Butterworth
Helen McCarthyHelen McCarthy
Helen McCarthy
ADAndrea Devlin
Andrea Devlin
LMLouise Ming
Louise Ming
TRTracy Robson
Tracy Robson
JWJenny Worthington
Jenny Worthington
Hypoxia confers resistance to common cancer therapies, however, it has also has been shown to result in genetic alterations which may allow a survival advantage and increase the tumorigenic properties of cancer cells. Additionally, it may exert a selection pressure, allowing expansion of tumor cells with a more aggressive phenotype. To further assess the role of hypoxia in malignant progression in prostate cancer we exposed human androgen dependent prostate cancer cells (LNCaP) to cycles of chronic hypoxia and isolated a subline, LNCaP‐H1. This article describes the partial characterization of this cell line. The LNCaP‐H1 subline showed altered growth characteristics and exhibited androgen independent growth both in vitro and in vivo. Furthermore, these cells were resistant to mitochondrial‐mediated apoptosis, probably since the endogenous levels of Bax was lower and Bcl‐2 higher than in the parental LNCaP cells. Microarray analysis revealed that a complex array of pathways had differential gene expression between the 2 cell lines, with LNCaP‐H1 cells exhibiting a genetic profile which suggests that they may be more likely metastasize to distant organs, especially bone. This was supported by an in vitro invasion assay, and an in vivo metastasis study. This study shows that hypoxia can select for androgen independent prostate cancer cells which have a survival advantage and are more likely to invade and metastasize.

10 March 2004 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
PDF file
JWJenny Worthington
Jenny Worthington
Helen McCarthyHelen McCarthy
Helen McCarthy
EBEimear Barrett
Eimear Barrett
CACatherine Adams
Catherine Adams
TRTracy Robson
Tracy Robson
DHDavid G Hirst
David G Hirst

23 August 2012 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
LMLouise Ming
Louise Ming
Niall ByrneNiall Byrne
Niall Byrne
SCSarah Nicole Camac
Sarah Nicole Camac
CMChristopher A. Mitchell
Christopher A. Mitchell
CWClaire Ward
Claire Ward
JWJenny Worthington
Jenny Worthington
Androgen withdrawal induces hypoxia in androgen‐sensitive tissue; this is important as in the tumour microenvironment, hypoxia is known to drive malignant progression. Our study examined the time‐dependent effect of androgen deprivation therapy (ADT) on tumour oxygenation and investigated the role of ADT‐induced hypoxia on malignant progression in prostate tumours. LNCaP xenografted tumours were treated with anti‐androgens and tumour oxygenation measured. Dorsal skin fold (DSF) chambers were used to image tumour vasculature in vivo. Quantitative PCR (QPCR) identified differential gene expression following treatment with bicalutamide. Bicalutamide‐treated and vehicle‐only‐treated tumours were re‐established in vitro, and invasion and sensitivity to docetaxel were measured. Tumour growth delay was calculated following treatment with bicalutamide combined with the bioreductive drug AQ4N. Tumour oxygenation measurements showed a precipitate decrease following initiation of ADT. A clinically relevant dose of bicalutamide (2 mg/kg/day) decreased tumour oxygenation by 45% within 24 hr, reaching a nadir of 0.09% oxygen (0.67 ± 0.06 mmHg) by Day 7; this persisted until Day 14 when it increased up to Day 28. Using DSF chambers, LNCaP tumours treated with bicalutamide showed loss of small vessels at Days 7 and 14 with revascularisation occurring by Day 21. QPCR showed changes in gene expression consistent with the vascular changes and malignant progression. Cells from bicalutamide‐treated tumours were more malignant than vehicle‐treated controls. Combining bicalutamide with AQ4N (50 mg/kg, single dose) caused greater tumour growth delay than bicalutamide alone. Our study shows that bicalutamide‐induced hypoxia selects for cells that show malignant progression; targeting hypoxic cells may provide greater clinical benefit.

16 October 2012 in British Journal of Cancer
Verified
Journal Article
Open access
GBG Browne
G Browne
HNH Nesbitt
H Nesbitt
LML Ming
L Ming
GSG S Stein
G S Stein
JLJ B Lian
J B Lian
JWJ Worthington
J Worthington
Background: Methods: Results: Conclusion:

19 July 2015 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
HNHeather Nesbitt
Heather Nesbitt
GBGillian Browne
Gillian Browne
KOKatie M. O'Donovan
Katie M. O'Donovan
Niall ByrneNiall Byrne
Niall Byrne
JWJenny Worthington
Jenny Worthington
DMDeclan J. McKenna
Declan J. McKenna

25 March 2014 in Annals of Microbiology
Verified
Journal Article
Closed access
PDF file
SRShazia Rashid
Shazia Rashid
AUAli Unyayar
Ali Unyayar
MMMehmet Ali Mazmanci
Mehmet Ali Mazmanci
SMStephanie R. McKeown
Stephanie R. McKeown
JWJenny Worthington
Jenny Worthington
Ibrahim M. BanatIbrahim M. Banat
Ibrahim M. Banat